title: Immunosuppressive therapy in dermatology and PML.
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.forename: Carlos
authors.initials: C
authors.lastname: Ferrandiz
authors.forename: Knud
authors.initials: K
authors.lastname: Kragballe
authors.forename: Kim
authors.initials: K
authors.lastname: Papp
authors.forename: Georg
authors.initials: G
authors.lastname: Stingl
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003880:Dermatology / Q000639:trends*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C472181:efalizumab